Potential conflict of interests forces board member out of Novo

This week, Novo Nordisk has said goodbye to one of its board members, Mary Szela. The reason is a potential conflict of interests related to Szela’s position as CEO of a US-based biotech company, which has moved into an area that Novo Nordisk also focuses on.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles